(Reuters) - The company said there was low probability of the trial achieving its main goal -- a reduction in crisis rate.
The company also said there were no statistically significant differences in safety measurements between the patient group being treated with its drug senicapoc and the group on placebo.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment